Skip to main content
. 2017 Jul 8;19(8):1613–1627. doi: 10.1093/pm/pnx151

Figure 1.

Figure 1

Sample and subsample descriptions and Ns. *Target products = crush-resistant tablets (reformulated oxycodone extended-release [ER], reformulated oxymorphone ER, and tapentadol ER), non–crush-resistant tablet formulation versions of these products, original/generic versions of oxycodone ER and oxymorphone ER, morphine ER, and oxycodone immediate-release single entity. CRT = crush-resistant tablet; MOA = mode of administration.